Wolverine Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-15,800
Closed -$20K 1897
2017
Q4
$20K Hold
15,800
﹤0.01% 1339
2017
Q3
$33K Sell
15,800
-100
-0.6% -$244 ﹤0.01% 1211
2017
Q2
$46K Sell
15,900
-6,900
-30% -$20.7K ﹤0.01% 1130
2017
Q1
$78K Sell
22,800
-42,100
-65% -$166K ﹤0.01% 974
2016
Q4
$112K Buy
64,900
+6,900
+12% +$16.2K ﹤0.01% 922
2016
Q3
$192K Buy
+58,000
New +$219K ﹤0.01% 878
2016
Q2
Sell
-53
Closed -$179K 1489
2016
Q1
$179K Sell
53
-344
-87% -$4.47K 0.01% 686
2015
Q4
$1.11M Sell
397
-69
-15% -$1.65K 0.02% 456
2015
Q3
$1.22M Sell
466
-20
-4% -$685 0.03% 452
2015
Q2
$413K Buy
486
+117
+32% +$7K 0.01% 707
2015
Q1
$167K Sell
369
-45
-11% -$2.79K ﹤0.01% 914
2014
Q4
$317K Sell
414
-67
-14% -$3.37K 0.01% 792
2014
Q3
$608K Buy
481
+320
+199% +$17.2K 0.01% 634
2014
Q2
$61K Buy
161
+125
+347% +$7.27K ﹤0.01% 1317
2014
Q1
$18K Buy
+36
New +$2.44K ﹤0.01% 1678
2013
Q4
Sell
-20
Closed -$19K 3197
2013
Q3
$19K Sell
20
-20
-50% -$1.35K ﹤0.01% 2053
2013
Q2
$46K Buy
+40
New +$2.46K ﹤0.01% 1730

Other funds holding OREX

Wolverine Asset Management's OREX Position: Q1 2018 in Review

Wolverine Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2018, closing a stake of 12,989 shares — an estimated $16K sold.

Wolverine Asset Management first reported a position in OREX in Q2 2013 and held it in 9 quarters. The position peaked at $338K in Q3 2014. 27 funds tracked by Wall St. Rank hold OREX as of Q1 2018.

  • Wolverine Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Wolverine Asset Management sold 12,989 Orexigen Therapeutics, Inc. shares in Q1 2018, an estimated $16K.
  • Wolverine Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 9 quarters.
  • Wolverine Asset Management's Orexigen Therapeutics, Inc. position peaked at $338K in Q3 2014.
  • 27 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2018.

Based on Wolverine Asset Management's 13F filing for Q1 2018, filed 15 May 2018.